All
Novel Combination Shows Survival Benefit in HER2-Positive Metastatic Breast Cancer
June 22nd 2020In order to combat resistance to certain treatments for patients with metastatic breast cancer, researchers look to a novel combination of pyrotinib plus Xeloda to help increase progression-free survival in patients.
FDA Approves Tazverik for Certain Patients With Relapsed/Refractory Follicular Lymphoma
June 18th 2020The Food and Drug Administration approved Tazverik for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and have received treatment with at least two systemic therapies, as well as patients who have no other treatment options.
FDA Approves Keytruda to Treat Tumor Mutational Burden-High Solid Tumors
June 17th 2020The Food and Drug Administration approved the second biomarker-based indication for Keytruda to treat adult and pediatric patients with unresectable or metastatic TMB-H solid tumors across cancer types, including rare cancers.
FDA Expands Mylotarg Approval to Include Children With Newly-Diagnosed CD33-Positive AML
June 16th 2020The Food and Drug Administration (FDA) extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive acute myeloid leukemia (AML).
FDA Grants Zepzelca Accelerated Approval to Treat Metastatic Small Cell Lung Cancer
June 16th 2020The Food and Drug Administration (FDA) has approved Zepzelca (lurbinectedin) for adults with metastatic small cell lung cancer (SCLC) whose disease progressed on or after receiving platinum-based chemotherapy.
FDA Approves HPV Vaccine Gardasil 9 for Certain Head and Neck Cancers
June 15th 2020The Food and Drug Administration (FDA) has granted accelerated approval to expand the indication of Gardasil 9 (Human papillomavirus 9-valent vaccine, recombinant), a vaccine for the prevention of HPV, to prevent oropharyngeal and other head and neck cancers caused by certain HPV types.
Survey Highlights the Unique Challenges Faced by Patients with MPNs
June 13th 2020Individuals living with myeloproliferative neoplasm (MPN) often face a markedly different experience compared to those patients with other types of blood cancer. Unfortunately, there tends to be less known about this population due to its smaller size. But tools like the recently published “Blood Cancer in America” 2020 survey aim to help highlight the disparities faced by the MPN community and give a voice to those who may feel unheard.